Cytokinetics Inc. (CYTK) intrinsic value & 10-year financials
Cytokinetics Inc. (CYTK) has a Graham intrinsic value of $1.46 per share. At $61.95 on Oct 17, 2026, the stock trades 4143% above that value. Over the last 10 fiscal years revenue shrank 2.1% a year to $88.0M, with an average return on invested capital of -100.3%.
- Graham intrinsic value
- $1.46
- Share price (Oct 17, 2026)
- $61.95
- Price vs Graham value
- 4143% above
- Market cap
- $7.4M
- Revenue (FY2025)
- $88.0M
- Revenue growth (10-yr CAGR)
- -2.1%
- ROIC (10-yr avg)
- -100.3%
- Free cash flow (FY2025)
- -$534.8M
CYTK 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $88.0M | -$785.0M | -$6.54 | -$534.8M | -695.4% | 306.5% |
| FY2024 | $18.5M | -$589.5M | -$5.26 | -$399.8M | -2902.7% | 331.7% |
| FY2023 | $7.5M | -$526.2M | -$5.45 | -$415.7M | -6589.7% | 339.5% |
| FY2022 | $94.6M | -$389.0M | -$4.33 | -$310.9M | -342.8% | -209.9% |
| FY2021 | $70.4M | -$215.3M | -$2.80 | -$191.4M | -264.5% | -101.3% |
| FY2020 | $55.8M | -$127.3M | -$1.97 | -$2.1M | -168.3% | -244.2% |
| FY2019 | $26.9M | -$121.7M | — | -$93.5M | -368.0% | -739.5% |
| FY2018 | $31.5M | -$106.3M | — | -$102.1M | -282.3% | -410.9% |
| FY2017 | $13.4M | -$127.8M | -$2.59 | -$104.6M | -848.3% | -307.4% |
| FY2016 | $106.4M | $16.5M | $0.39 | $35.4M | 17.6% | 32.6% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CYTOKINETICS INC is facing top-line stagnation, with revenue contracting over the decade.
CYTOKINETICS INC has historically struggled to out-earn its cost of capital, averaging just -7.8% ROIC.
Over the decade, CYTOKINETICS INC shows that management has aggressively returned capital to shareholders by retiring 99.7% of outstanding shares, and that the company has leveraged its balance sheet to sustain operations.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CYTOKINETICS INC is modeled at -2.1% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $1.46 per share.